Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies

Sanchez-Piedra, C.; Diaz-Torne, C.; Manero, J.; Pego Reigosa, José María; Rua-Figueroa, I.; Gonzalez-Gay, M. A.; Gómez-Reino Carnota, Juan Jesús; Alvaro-Gracia, J. M.; Biobadaser Study Group

Statistics

Statistics

View Usage Statistics

Identifiers

Identifiers

URI: http://hdl.handle.net/20.500.11940/16693

PMID: 32503857

DOI: 10.1136/annrheumdis-2020-217948

ISSN: 0003-4967

Full record

Services

Services

RIS

Mendeley

Linksolver

Files view or download

Files view or download

Ann Rheum Dis . 2020 Jul;79(7):988-990 (273.6Kb)

Date issued

2020

Journal title

Annals of the rheumatic diseases

Type of content

Journal Article

DeCS

pandemias | glucocorticoides | mediana edad | anticuerpos | adulto | antirreumáticos | anciano | neumonía | metotrexato | hospitalización | enfermedades reumáticas | humanos | espondiloartropatías | unidades de cuidados intensivos | hidroxicloroquina | infecciones por Coronavirus | artritis | proteína antagonista del receptor de interleucina 1

MeSH

Spondylarthropathies | Rheumatic Diseases | Pandemics | Adult | Middle Aged | Coronavirus Infections | Glucocorticoids | Pneumonia | Methotrexate | Arthritis | Antibodies | Hospitalization | Humans | Antirheumatic Agents | Interleukin 1 Receptor Antagonist Protein | Hydroxychloroquine | Intensive Care Units | Aged

Atribución-NoComercial 4.0 Internacional

Except where otherwise noted, this item's license is described as Atribución-NoComercial 4.0 Internacional